Is Cumberland Pharmaceuticals Inc. (CPIX) a Buy, Sell, or Hold?
NASDAQ : CPIX
Cumberland Pharmaceuticals Inc.
$6.84 USD
-$0.82 (-10.7%)
- Volume
- 239.78K
- Average Volume
- 995.62K
- Market Capitalization
- $102.48M
- P/E Ratio
- -13.83
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $8.09
- Year Low
- $1.85
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.95
Company Overview
NASDAQ
A. J. Kazimi
Drug Manufacturers - Specialty & Generic
Healthcare
CPIX
93
US
USD
Liquidity Metrics
0.47
0.95
0.79
0.32
0.00
Sales & Valuation
$44.52M
2.44
4.73
77.73
0.09
Profitability
-$0.19
-$2.84M
-17.24%
-17.20%
-28.75%
-10.19%
P/E Metrics
-13.83
0.08
0.08
Analyst Price Target & Rating
2/5
5 Analysts
%
Poll Results
About Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Stock
Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastroenterology, rheumatology, and oncology, with operations spanning both the United States and global markets. The company's existing product line includes: Acetadote: an injectable solution for treating acetaminophen poisoning. Caldolor: an injectable medication for managing pain and fever. Kristalose: a prescription oral laxative solution effective for chronic and acute constipation. Omeclamox-Pak: used in the treatment of Helicobacter pylori infection and duodenal ulcer disease. Vaprisol: an injectable therapy for euvolemic and hypervolemic hyp ... onatremia. Vibativ: an injectable antibiotic prescribed for severe bacterial infections, including those acquired in hospitals or associated with ventilators, as well as complex skin and skin structure infections. In its development pipeline, Cumberland is advancing: RediTrex injection: designed to treat active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, along with disabling psoriasis. Ifetroban: a product candidate currently in Phase II clinical trials for aspirin-exacerbated respiratory disease, systemic sclerosis, and Duchenne muscular dystrophy. It has also completed Phase II clinical trials for hepatorenal syndrome and portal hypertension, with further clinical investigation ongoing for its potential use in progressive fibrosing interstitial lung diseases. An additional product candidate in Phase II clinical trials, aimed at reducing cholesterol levels for hospital use. Founded in 1999, the company's corporate headquarters are located in Nashville, Tennessee.
ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now?
2026-07-15 12:26:08
Elite Pharmaceuticals and Cumberland Pharmaceuticals follow different growth paths, but which looks more compelling now? Let's dive in.
/C O R R E C T I O N -- Cumberland Pharmaceuticals Inc./
2026-07-13 12:00:00
/C O R R E C T I O N -- Cumberland Pharmaceuticals Inc./ PR Newswire NASHVILLE, Tenn., July 13, 2026
CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE
2026-07-13 11:00:00
CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE PR Newswire NASHVILLE, Tenn., July 13,
CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE
2026-07-13 10:46:00
Record Date is July 10, 2026 & Payment Date is July 31,2026 Corporate and Insider Share Purchase Initiatives to Continue NASHVILLE, Tenn., July 13, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases, announced today that its Board of Directors has authorized and declared a special cash dividend of $1.50 per share of the Company's common stock.
Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals
2026-07-01 09:00:00
TORONTO, July 1, 2026 /PRNewswire/ - Apotex Health Corp. ("Apotex") (TSX: APTX), the largest Canadian-based pharmaceutical company, today announced the closing of its previously announced strategic transaction with Cumberland Pharmaceuticals Inc. ("Cumberland"), a U.S. biopharmaceutical company, to integrate Cumberland's U.S. branded businesses into Apotex. With the completion of the strategic transaction, Apotex adds a portfolio of established branded medicines to its U.S. business, expanding its specialty and hospital-focused presence across key therapeutic areas including acute care, oncology, infectious disease, and gastroenterology.
Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex
2026-07-01 09:00:00
$100 million Transaction Follows Cumberland Shareholder Approval Strengthens Cumberland's Focus on Rare Disease Pipeline NASHVILLE, Tenn., July 1, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a U.S. biopharmaceutical company, today announced the closing on an agreement with subsidiary of Apotex Health Corp. ("Apotex"), the largest Canadian-based pharmaceutical company, to integrate their branded U.S. businesses.
2026-06-26 12:00:00
Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference PR
2026-06-26 11:00:00
Additional cardiac biomarker analyses further demonstrate ifetroban's cardioprotective effect in DMD patients NASHVILLE, Tenn., June 26, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, today shared updated results from its Phase 2 FIGHT DMD trial evaluating ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease, at the annual Parent Project Muscular Dystrophy (PPMD) conference in Orlando, Florida.
Frequently Asked Questions
-
What is the current Cumberland Pharmaceuticals Inc. (CPIX) stock price?
-
Cumberland Pharmaceuticals Inc.(NASDAQ:CPIX) stock price is $6.84 in the last trading session. During the trading session, CPIX stock reached the peak price of $8.09 while $1.85 was the lowest point it dropped to. The percentage change in CPIX stock occurred in the recent session was --10.7% while the dollar amount for the price change in CPIX stock was -$0.82.
-
CPIX's industry and sector of operation?
-
The NASDAQ listed CPIX is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of CPIX?
-
Adam S. Mostafa | Managing Director of Banking & Investor Relations
A. J. Kazimi | Founder, Chairman, President & Chief Executive Officer
ChristopherT. Bitterman | Vice President of Sales & Marketing
James Lowrance Herman | Vice President of Trade & Distribution and Chief Compliance Officer
John Michael Hamm | Vice President Accounting & Finance and CFO -
How many employees does CPIX have?
-
Number of CPIX employees currently stands at 93. CPIX operates from 2525 West End Avenue, Nashville, TN 37203, US.
-
Link for CPIX official website?
-
Official Website of CPIX is: https://www.cumberlandpharma.com
-
How do I contact CPIX?
-
CPIX could be contacted at phone #615 255 0068 and can also be accessed through its website. CPIX operates from 2525 West End Avenue, Nashville, TN 37203, US.
-
How many shares of CPIX are traded daily?
-
The average number of CPIX shares traded daily for last 3 months was 995.62K.
-
What is the market cap of CPIX currently?
-
The market value of CPIX currently stands at $102.48M with its latest stock price at $6.84